Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 12/20 | 0.63 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637992 | 0.90 | CRACR2A (0.53) | CRACR2AMAPTGAAHPGDSMN1; SMN2 | |
| SCHEMBL1669149 | 0.87 | CRACR2A (0.66) | CRACR2AORAI1 | |
| SCHEMBL1888614 | 0.84 | CRACR2A (0.62) | CRACR2AORAI1MAPTGAA | |
| SCHEMBL1879508 | 0.78 | CRACR2A (1.00) | CRACR2AORAI1 | |
| SCHEMBL1881601 | 0.78 | CRACR2A (1.00) | CRACR2AORAI1MAPTGAASMN1; SMN2 | |
| SCHEMBL1667962 | 0.75 | CRACR2A (1.00) | CRACR2AORAI1SMN1; SMN2 | |
| SCHEMBL1667966 | 0.75 | CRACR2A (0.81) | CRACR2AORAI1KCNJ6KCNJ3 | |
| SCHEMBL1883281 | 0.74 | CRACR2A (0.75) | CRACR2AORAI1 | |
| SCHEMBL12637994 | 0.74 | EPHX2 (0.59) | CRACR2AMAPTGAASMN1; SMN2 | |
| SCHEMBL12637829 | 0.74 | CRACR2A (0.68) | CRACR2AORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| EP-3299361-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2018-03-28 | — | — | EP | claimed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | claimed |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-18 | — | — | US | claimed |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Phamaceuticals SA (CH) | 2013-11-21 | — | — | US | claimed |
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| EP-2509955-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| WO-2011042797-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | ICOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885MAPT 3801/4885 |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885MAPT 3875/4885 |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885MAPT 3801/4885 |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885MAPT 3801/4885 |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885MAPT 3801/4885 |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885MAPT 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.